[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614933":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":11,"armGroups":49,"interventions":59,"overallOfficials":11,"centralContacts":69,"locations":75,"responsibleParty":172,"collaborators":11,"id":174,"slug":11,"hasResults":175,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":11,"eligibilityCriteria":179,"healthyVolunteers":175,"sex":180,"minAge":181,"maxAge":11,"enrollmentInfo":182,"targetDuration":11,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":11,"overallStatus":122,"whyStopped":11,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":200},{"fullName":5,"class":6},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":27,"otherOutcomes":11},[9,13,16,18,21,24],{"measure":10,"description":11,"timeFrame":12},"Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.",null,"around 6 months.",{"measure":14,"description":11,"timeFrame":15},"Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months","around 6 months",{"measure":17,"description":11,"timeFrame":15},"Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months",{"measure":19,"description":11,"timeFrame":20},"Part B:A platelet count of ≥100×109\u002FL within 14 days after initiating the investigational product treatment, around 3 years","around 3 years",{"measure":22,"description":11,"timeFrame":23},"Part B:No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until Cycle 2 Day 21, around 3 years.","around 3 years.",{"measure":25,"description":11,"timeFrame":26},"Part B:Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years;","around 3 years;",[28,30,32,34,36],{"measure":29,"description":11,"timeFrame":26},"Proportion of participants achieving platelet count ≥100×109\u002FL without the use of rescue therapy within 14 days after initiating the investigational product treatment,around 3 years;",{"measure":31,"description":11,"timeFrame":26},"platelet count nadir from Cycle 1 Day 1 until Cycle 2 Day 21, around 3 years;",{"measure":33,"description":11,"timeFrame":26},"Proportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until C2D21, around 3 years;",{"measure":35,"description":11,"timeFrame":23},"Proportion of participants with neutropenia during the treatment period from the initiation of IP treatment until Cycle 2 Day 21, around 3 years.",{"measure":37,"description":11,"timeFrame":23},"Number of Adverse Events\u002FSerious Adverse Events, safety lab parameters, vital signs, etc within study period, around 3 years.",{"allocation":39,"interventionModel":40,"interventionModelDescription":11,"primaryPurpose":41,"observationalModel":11,"timePerspective":11,"maskingInfo":42},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":43,"maskingDescription":11,"whoMasked":44},"QUADRUPLE",[45,46,47,48],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[50,55],{"label":51,"type":52,"description":11,"interventionNames":53},"Part A: Hetrombopag Olamine","EXPERIMENTAL",[54],"Drug: Hetrombopag Olamine",{"label":56,"type":52,"description":11,"interventionNames":57},"Part B：Hetrombopag Olamine vs Hetrombopag Olamine Placebo",[58],"Drug: Hetrombopag Olamine ；Hetrombopag Olamine Placebo",[60,65],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"DRUG","Hetrombopag Olamine","For Part A, all participants would receive hetrombopag treatment.",[51],{"type":61,"name":66,"description":67,"armGroupLabels":68,"otherNames":11},"Hetrombopag Olamine ；Hetrombopag Olamine Placebo","For Part B，participants would be randomized to receive hetrombopag treatment or matching placebo, respectively。",[56],[70],{"name":71,"role":72,"phone":73,"phoneExt":11,"email":74},"Junye Xiong","CONTACT","0518-82342973","junye.xiong@hengrui.com",[76,94,107,120,133,146,159],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Cancer and Blood Specialty Clinic","NOT_YET_RECRUITING","Los Alamitos","California","90254","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-118.07256,33.80307,{"lat":88,"lon":87},[91],{"name":92,"role":93,"phone":11,"phoneExt":11,"email":11},"Arati Chand","PRINCIPAL_INVESTIGATOR",{"facility":95,"status":78,"city":96,"state":97,"zip":98,"country":82,"countryCode":83,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology","Denver","Colorado","80210",{"type":85,"coordinates":100},[101,102],-104.9847,39.73915,{"lat":102,"lon":101},[105],{"name":106,"role":93,"phone":11,"phoneExt":11,"email":11},"Yousuf Gaffar",{"facility":108,"status":78,"city":109,"state":110,"zip":111,"country":82,"countryCode":83,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Oncology & Hematology Associates of West Broward","Coral Springs","Florida","33065",{"type":85,"coordinates":113},[114,115],-80.2706,26.27119,{"lat":115,"lon":114},[118],{"name":119,"role":93,"phone":11,"phoneExt":11,"email":11},"Sumit Sawhney",{"facility":121,"status":122,"city":123,"state":110,"zip":124,"country":82,"countryCode":83,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Mid-Florida Hematology & Oncology Centers, P.A.","RECRUITING","Orange City","32763",{"type":85,"coordinates":126},[127,128],-81.29867,28.94888,{"lat":128,"lon":127},[131],{"name":132,"role":93,"phone":11,"phoneExt":11,"email":11},"Santosh Nair",{"facility":134,"status":78,"city":135,"state":136,"zip":137,"country":82,"countryCode":83,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Springfield Clinic","Springfield","Illinois","62702",{"type":85,"coordinates":139},[140,141],-89.64371,39.80172,{"lat":141,"lon":140},[144],{"name":145,"role":93,"phone":11,"phoneExt":11,"email":11},"Preet Singh",{"facility":147,"status":78,"city":148,"state":149,"zip":150,"country":82,"countryCode":83,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Morristown Medical Center","Morristown","New Jersey","07039",{"type":85,"coordinates":152},[153,154],-74.48154,40.79677,{"lat":154,"lon":153},[157],{"name":158,"role":93,"phone":11,"phoneExt":11,"email":11},"Se young Han",{"facility":160,"status":78,"city":161,"state":162,"zip":163,"country":82,"countryCode":83,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"New York Cancer and Blood Specialists One Oncology","Shirley","New York","11967",{"type":85,"coordinates":165},[166,167],-72.8676,40.80149,{"lat":167,"lon":166},[170],{"name":171,"role":93,"phone":11,"phoneExt":11,"email":11},"Richard Zuniga",{"type":173,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614933",false,"NCT07286032","A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia","A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia","Inclusion Criteria:\n\n1. Male or female gender, age ≥18 years at screening.\n2. Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma \\[NSCLC\\], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon\u002Fcolorectal cancer).\n3. Receiving platinum- and\u002For gemcitabine-containing chemotherapy regimens on 21-day treatment cycles.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.\n5. Life expectancy ≥6 months.\n6. Signed ICF for voluntary participation in the study and good compliance.\n\nExclusion Criteria:\n\n1. Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).\n2. Hematologic malignancies.\n3. Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.\n4. Untreated brain metastases; or with leptomeningeal metastasis.\n5. Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).\n6. Severe cardiovascular disorders or interventions within 6 months\n7. Have arterial\u002Fvenous thrombosis within 6 months\n8. Known bleeding disorders, platelet dysfunction\n9. Severe haemorrhage during screening\n10. Acute or uncontrolled hepatitis B\\&C infection\n11. Human immunodeficiency virus (HIV) infection.","ALL","18 Years",{"count":183,"type":184},150,"ESTIMATED","INTERVENTIONAL",[187],"PHASE3","The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.",[190],"Patients With Chemotherapy-Induced Thrombocytopenia","2026-04-24",{"date":193,"type":194},"2026-04-30","ACTUAL",{"date":196,"type":194},"2026-04-16",{"date":198,"type":184},"2029-06",{"name":5,"class":6},7]